Enterprise Value
41.79M
Cash
19.16M
Avg Qtr Burn
-11.1M
Short % of Float
5.85%
Insider Ownership
27.01%
Institutional Own.
49.10%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Upneeq (RVL-1201) Details Blepharoptosis | Approved Quarterly sales | |
Arbaclofen extended-release (ER) Details Multiple sclerosis, Central nervous system illness | Failed Discontinued |